Ontology highlight
ABSTRACT:
SUBMITTER: Peyvandi F
PROVIDER: S-EPMC6055565 | biostudies-literature | 2018 Apr
REPOSITORIES: biostudies-literature
Peyvandi Flora F Garagiola Isabella I
Research and practice in thrombosis and haemostasis 20180410 2
The development of FVIII inhibitory antibodies is currently the most challenging complication of treatment, affecting ~30% of severe hemophilia A patients. These inhibitors inactivate FVIII, rendering the treatment ineffective, causing disability and increasing morbidity and mortality. Inhibitor development results from a complex multicausal immune response involving both genetic and environmental risk factors. One of the most important modifiable risk factors is the source of FVIII products, eg ...[more]